| Autor: |
Ye, Je‐Chiuan, Hsieh, Yih‐Shou, Chen, Pei‐Ni, Liu, Jer‐Yuh, Hsieh, Yi‐Hsien |
| Předmět: |
|
| Zdroj: |
Drug Development Research; Jun2023, Vol. 84 Issue 4, p767-776, 10p |
| Abstrakt: |
Our previous studies have shown that the plasminogen activator (PA) and matrix metalloproteinases (MMPs) proteinase systems were highly expressed in highly malignant liver cancer cells and regulated by PKCα. This study investigates whether the PKCα regulation of PA and MMPs systems is conducted through p38 mitogen‐activated protein kinase (MAPK) signaling and the pathway is responsible for promoting cell progression. We found that the expressions of p38 MAPK in both highly malignant HA22T/VGH and SK‐Hep‐1 liver cancer cells were higher than that in other lower malignancy liver cancer cells. Since PKCα activates p38 MAPK in progression of liver cancer, we suspected the PKCα/p38 MAPK signaling pathway to be involved in the regulation of MMPs and PA systems. When SK‐Hep‐1 cells were treated with SB203580 or DN‐p38, only MMP‐1 and u‐PA mRNA expressions decreased. The p38 MAPK inhibition also decreased the cell migration and invasion. In addition, the mRNA decay assays showed that the higher expressions of MMP‐1 and u‐PA mRNA in SK‐Hep‐1 cells were due to the alteration of mRNA stability by p38 MAPK inhibition. Zymography of SK‐Hep‐1 cells treated with siPKCα vector also showed the decrease of the activity of MMP‐1 and u‐PA and confirmed changes in mRNA level. Furthermore, only the transfection of MKK6 to the siPKCα‐treated SK‐Hep‐1 stable clone cell restored the attenuation of MMP‐1 and u‐PA expressions. The treatment of SK‐Hep‐1 cells with either inhibitor of MMP‐1 or u‐PA reduced migration, and the reduction was enhanced with both inhibitors. In addition, tumorigenesis was also reduced with both inhibitors. These data suggest a novel finding that MMP‐1 and u‐PA are critical components in PKCα/MKK6/p38 MAPK signaling pathway which mediates liver cancer cell progression, and that the targeting of both genes may be a viable approach in liver cancer treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text